Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) is anticipated to announce its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Kyverna Therapeutics to post earnings of ($1.21) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.01). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Trading Down 4.5 %

Shares of NASDAQ KYTX traded down $0.10 during mid-day trading on Tuesday, reaching $2.04. The company had a trading volume of 2,952 shares, compared to its average volume of 413,328. The stock has a market cap of $87.95 million, a price-to-earnings ratio of -0.60 and a beta of 2.17. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $17.55. The business's 50-day moving average is $2.23 and its 200-day moving average is $3.44.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE raised its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 41.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,788 shares of the company's stock after buying an additional 6,400 shares during the quarter. Bank of America Corp DE owned about 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.08% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KYTX. HC Wainwright decreased their price target on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating for the company in a research note on Thursday, April 3rd. Morgan Stanley decreased their target price on Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating for the company in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Kyverna Therapeutics has a consensus rating of "Buy" and an average target price of $18.33.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.